Recognized by DARPA and Bayer Pharmaceuticals
Quorum Innovations has been recognized by both the Defense Advanced Research Projects Agency (DARPA) and Bayer Pharmaceuticals for its pioneering microbiome-derived barrier defense technologies.
DARPA selected Quorum to develop microbial protective barrier therapeutics capable of defending against chemical and biological threats, awarding the company two research grants to advance this critical work for protecting warfighters and first responders.
In parallel, Bayer Pharmaceuticals recognized the potential of Quorum’s platform for civilian applications, collaborating on a women’s health initiative to develop microbiome-based formulations for barrier defense in intimate care products.
The same scientific principles—preventing harmful particles from crossing epithelial barriers—underlie these innovations and extend to broader modern health challenges. This technology offers powerful applications in shielding against environmental toxins, including the absorption of microplastics and nanoplastics, as well as supporting epithelial integrity, reducing inflammation in skin and gut conditions, and addressing immune imbalances driven by urban living, chronic stress, and dietary disruptions.